Gastrointestinal Cancer

Gastrointestinal Cancer

Adding cetuximab to FOLFIRI resulted in improvements in survival and objective response in patients with KRAS codon exon 2 wild-type metastatic colorectal cancer.

The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the results of a phase II study.

Combining MM-398 with 5-FU/leucovorin chemotherapy in metastatic pancreatic cancer patients resulted in improved survival compared with 5-FU/leucovorin alone.

Hepatocellular carcinoma patients with baseline alpha-fetoprotein (AFP) levels greater than 400 ng/mL may derive greater benefit from second-line ramucirumab.

The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.

Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.

Rectal cancer patients who completed neoadjuvant therapy with a clinical complete response had similar 4-year survival rates as patients who opted for surgery.


Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.